Recombinant Tissue Plasminogen Activator (Rtpa) and Stroke Unit for Acute Ischaemic Stroke in Developing Countries,Are They Cost-Effective?

Abstract

Get full access to this article

View all access options for this article.

References

Sandercock

Berge

Dennis

Cost-effectiveness of thrombolysis with recombinant tissue plasminogen activator for acute ischemic stroke assessed by a model based on UK NHS costs. Stroke 2004; 35:1490–7.

Epifanov

Dodel

Haacke

Costs of acute stroke care on regular neurological wards: a comparison with stroke unit setting. Health Policy 2007; 81:339–49.

Marini

Russo

Felzani

Incidence of stroke in young adults: a review. Stroke Res Treat 2010; 2011:535672.

Hamad

Sokrab

T.E.

Momeni

Mesraoua

Lingren

Stroke in Qatar: a one-year, hospital-based study. J Stroke Cerebrovasc Dis 2001; 10:236–41.

Ghandehari

Barriers of thrombolysis therapy in developing countries. Stroke Res Treat 2011; 2011:686797.